返回 Agenda
Session Chair(s)
David B. Jefferys, MD, FRCPC
Senior Vice President
EISA EUROPE LTD, United Kingdom
Speaker(s)
New Approaches to the Approval of Innovative Medicines: The EMA Perspective
Tomas Salmonson, DrMed, PHD
Critical Path Institute, Netherlands
PMDA’s Approaches to the Approval of Innovative Medicines: How Does Sakigake Work?
Toshiyoshi Tominaga, PHD
SunFlare Co., Ltd, Japan
Life Science Department, Advisor
Comparing the Characteristics and Use of Facilitated Regulatory Pathways by ICH and Maturing Agencies
Lawrence Liberti, PHD, RAC
The Kim Center/ USC DRQS, United States
Director, D.K. Kim International Center for Regulatory Science
Panel Discussion- Patient Perspective
Alastair Kent, MHS
Genetic Alliance UK, United Kingdom
Co-Chair of the UK Rare Disease Policy Board; Former Executive Director